1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Atonic Neurogenic Bladder Global Clinical Trials Review, H2, 2015

Atonic Neurogenic Bladder Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Atonic Neurogenic Bladder Global Clinical Trials Review, H2, 2015" provides an overview of Atonic Neurogenic Bladder clinical trials scenario. This report provides top line data relating to the clinical trials on Atonic Neurogenic Bladder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Atonic Neurogenic Bladder Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Atonic Neurogenic Bladder to Genito Urinary System And Sex Hormones Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Atonic Neurogenic Bladder to Genito Urinary System And Sex Hormones Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Atonic Neurogenic Bladder Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profile Snapshots 28
Appendix 39
Abbreviations 39
Definitions 39
Research Methodology 40
Secondary Research 40
About GlobalData 41
Contact Us 41
Disclaimer 41
Source 42

List of Tables
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials by Region, 2015* 6
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 9
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 10
Atonic Neurogenic Bladder Therapeutics Clinical Trials, North America, Top Countries, 2015* 11
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 12
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 13
Proportion of Atonic Neurogenic Bladder to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2015* 14
Atonic Neurogenic Bladder Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Atonic Neurogenic Bladder Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Atonic Neurogenic Bladder to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2015* 17
Atonic Neurogenic Bladder Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials by Phase, 2015* 19
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 20
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials by Trial Status, 2015* 21
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Global, by End Point Status, 2015* 22
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 23
Atonic Neurogenic Bladder Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 24
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 25
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 26
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 27

List of Figures
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 9
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 10
Atonic Neurogenic Bladder Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 11
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 12
Proportion of Atonic Neurogenic Bladder to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2015* 14
Atonic Neurogenic Bladder Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Atonic Neurogenic Bladder Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Atonic Neurogenic Bladder to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2015* 17
Atonic Neurogenic Bladder Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials by Phase (%), 2015* 19
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 20
Atonic Neurogenic Bladder Therapeutics, Global, Clinical Trials by Trial Status, 2015* 21
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Global, by End Point Status, 2015* 22
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 23
Atonic Neurogenic Bladder Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 24
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 25
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 26
Atonic Neurogenic Bladder Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 27
GlobalData Methodology 40

Companies Mentioned
Sanofi
Astellas Pharma Inc.
Visiting Nurse Service of New York
Allergan Plc
Riemser Pharma GmbH
Novartis AG
JW Pharmaceutical Corporation
Dong-A Socio Group
C. H. Boehringer Sohn AG and Co. KG

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.